hczong
Lv4
760 积分
2022-10-25 加入
-
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
12天前
已完结
-
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
12天前
已完结
-
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
13天前
已完结
-
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
1个月前
已完结
-
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
2个月前
已完结
-
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
2个月前
已完结
-
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
2个月前
已完结
-
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
2个月前
已完结
-
Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response
2个月前
已完结
-
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
2个月前
已完结